Blog
RSS FeedPosted by Michael Wonder on 21 Aug 2019
NICE’s fast-track catapults Skyrizi into market
21 August 2019 - Watchdog also gives direction on comparing rival treatments. ...
Posted by Michael Wonder on 15 Aug 2019
Advanced ovarian cancer drug gets initial 'no' for NHS in England
15 August 2019 - A targeted drug with potential to slow the progress of ovarian cancer has been rejected for ...
Posted by Michael Wonder on 08 Aug 2019
New lung cancer treatment option approved by NICE
8 August 2019 - Another new life-extending treatment for some people with lung cancer is to be made available on the ...
Posted by Michael Wonder on 07 Aug 2019
NICE recommends additional treatment option for people with early breast cancer
7 August 2019 - NICE has today published draft guidance recommending neratinib as an additional treatment for some people with early ...
Posted by Michael Wonder on 03 Aug 2019
NICE expands draft recommendation for Lokelma
31 July 2019 - AstraZeneca has announced that the NICE has issued a positive Final Appraisal Document for Lokelma (sodium ...
Posted by Michael Wonder on 01 Aug 2019
NICE backs Bayer’s Xarelto in new stroke and heart attack prevention use
1 August 2019 - Bayer’s Xarelto (rivaroxaban) can be funded by the NHS to prevent strokes and heart attacks in ...
Posted by Michael Wonder on 26 Jul 2019
Innovative treatment for gynaecological cancers approved for Cancer Drugs Fund
26 July 2019 - Olaparib, a medicine that has previously been used at a later stage in the treatment of advanced ...
Posted by Michael Wonder on 15 Jul 2019
NICE recommends Skyrizi, Forxiga
15 July 2019 - NICE has recommended two new drugs on the NHS, AbbVie’s Skyrizi (risankizumab) and AstraZeneca’s Forxiga (dapagliflozin) ...
Posted by Michael Wonder on 12 Jul 2019
NICE recommends innovative treatment for type 1 diabetes
12 July 2019 - It’s estimated that around 90,000 people could be eligible for treatment with dapagliflozin. ...
Posted by Michael Wonder on 09 Jul 2019
NICE Onpattro approval puts Alnylam back in hATTR running
9 July 2019 - NICE has recommended the use of Alynylam’s Onpattro (patisiran), after issuing a preliminary ‘no’, back in ...
Posted by Michael Wonder on 07 Jul 2019
AZ appeals against NICE rejection of Tagrisso in untreated lung cancer
5 July 2019 - AstraZeneca is appealing against NICE’s decision not to recommend funding for its lung cancer drug Tagrisso ...
Posted by Michael Wonder on 05 Jul 2019
Device for preventing and relieving pain of cluster headaches approved by NICE in draft guidance
5 July 2019 - A handheld device that delivers a small electric current has been recommended by NICE for the prevention ...
Posted by Michael Wonder on 05 Jul 2019
Life-extending lung cancer treatment recommended for use on the NHS
5 July 2019 - Dacomitinib has been recommended as a first-line treatment option for people with a type of non-small-cell lung ...
Posted by Michael Wonder on 04 Jul 2019
Spinraza access agreement extended
3 July 2019 - More children with the rare genetic disorder spinal muscular atrophy can now be treated with Spinraza after ...
Posted by Michael Wonder on 02 Jul 2019
Immediately after EU nod, England’s NHS funds Sanofi skin cancer drug
2 July 2019 - Patients in England will be among those who are first to benefit from Sanofi and Regeneron’s ...